NRAS and neoplasm: In the first case, a 13-year-old presented with PCI of 16 and neoadjuvant chemotherapy-responsive disease and proceeded to CRS and HIPEC plus ultrasound ablation of hepatic capsule implants, followed by adjuvant trametinib and chemotherapy for an oncogenic NRAS mutation on tumor sequencing.